Citius Pharmaceuticals Inc CTXR

$0.54 +0.00 (0.51%)

Valuation

Market cap
14,690,000
Revenue TTM
$0
Net income TTM
$-37,430,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.08

Trading

Volume
173,100
Avg volume
237,086
Day's range
$0.50 – $0.55
Shares out
27,453,000
Stochastic %K
39%
Beta
1.05
Analysts
Moderate Buy
Price target
$4.00

Price

Company profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroi...

Show more

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
908 967 6677
Website
https://citiuspharma.com
Address
11 Commerce Drive, First Floor, Cranford, United States

Latest news

No headlines yet.